Bionano Genomics (BNGO) Equity Ratio (2017 - 2026)

Bionano Genomics has disclosed Equity Ratio across 10 years of filings, most recently posting 0.58 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.58, down 5.93% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.58 (down 5.93% YoY), and the FY2025 annual result was 0.6, up 30.85% from the prior year.
• Equity Ratio came in at 0.58 for Q1 2026 at Bionano Genomics, down from 0.6 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2022 to a low of 0.45 in Q4 2023.
• The 5-year median for Equity Ratio is 0.62 (2024), against an average of 0.67.
• Across the five-year window, Equity Ratio sank 44.7% in 2023 and surged 30.85% in 2025, its largest moves.
• Bionano Genomics' Equity Ratio stood at 0.81 in 2022, then tumbled by 44.7% to 0.45 in 2023, then climbed by 2.88% to 0.46 in 2024, then jumped by 30.85% to 0.6 in 2025, then dropped by 4.24% to 0.58 in 2026.
• The last three Equity Ratio figures came in at 0.58 (Q1 2026), 0.6 (Q4 2025), and 0.63 (Q3 2025), per Business Quant data.